SEC Form 4 · accession 0001437749-18-016812
Oxford Immunotec Global PLC · OXFD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter Wrighton-Smith
Officer — Chief Executive Officer · Director
Period of report
Sep 7, 2018
Accepted (ET)
Sep 10, 2018 · 4:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586049
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Sep 7, 2018 | M | 40,000 | $0.81 | A | 525,296 | D | |
| Ordinary Shares | Sep 7, 2018 | S | 40,000 | $14.95 | D | 485,296 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $0.81 | Sep 7, 2018 | M | 40,000 | D | — | Dec 31, 2022 | Ordinary Shares | 40,000 | 54,273 | D |
Explanation of responses
- F1The original exercise price of these options was priced in GBP at GBP0.51 and converted to US$ at an exchange rate of US$1.58823=1GBP.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 10, 2015, as amended.
- F3Exercise from an option granted November 7, 2012, which became fully vested on December 31, 2016.